The vast majority of investigator brochures lack sufficient information to systematically appraise the strength of the supporting preclinical findings.

The article reports that the vast majority of investigator brochures lack sufficient information to systematically appraise the strength of the supporting preclinical findings as per investigation of 109 investigator brochures (IBs) reported in an April 2018 issue of the journal "PLoS Biology." Topics include the IBs covered 8 of 12 therapeutic areas as distinguished by the European Medicines Agency.